🇺🇸 FDA
Pipeline program

Coagulation Factor VIIa (Recombinant)

F7TG2202

Phase 3 mab terminated

Quick answer

Coagulation Factor VIIa (Recombinant) for Hemophilia is a Phase 3 program (mab) at Laboratoire HRA Pharma with 1 ClinicalTrials.gov record(s).

Program details

Company
Laboratoire HRA Pharma
Indication
Hemophilia
Phase
Phase 3
Modality
mab
Status
terminated

Clinical trials